A practical reference on circadian clock: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-27 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
== Importance in nuclear reactors == If a nuclear reactor happened to be prompt critical – even very slightly – the number of neutrons would increase exponentially at a high rate, and very quickly the reactor would become uncontrollable by means of external mechanisms. The control of the power rise would then be left to its intrinsic physical stability factors, like the thermal dilatation of the core, or the increased resonance absorptions of neutrons, that usually tend to decrease the reactor's reactivity when temperature rises; but the reactor would run the risk of being damaged or destroyed by heat. However, thanks to the delayed neutrons, it is possible to leave the reactor in a subcritical state as far as only prompt neutrons are concerned: the delayed neutrons come a moment later, just in time to sustain the chain reaction when it is going to die out. In that regime, neutron production overall still grows exponentially, but on a time scale that is governed by the delayed neutron production, which is slow enough to be controlled (just as an otherwise unstable bicycle can be balanced because human reflexes are quick enough on the time scale of its instability). For example, with a neutron lifetime of 10−3 s and a reactivity step of 0.0022, the reactor period would be 0.45 s without delayed neutrons, but is 14 s with them. Thus, by widening the margins of non-operation and supercriticality and allowing more time to regulate the reactor, the delayed neutrons are essential to inherent reactor safety, even in reactors requiring active control.
== Career and research == In 1984, Drucker began his research career at Massachusetts General Hospital and Harvard Medical School, studying molecular endocrinology in the lab of Professor Joel Habener with the support from a Medical Research Council of Canada Centennial Fellowship. Drucker’s independent discoveries in Boston included the demonstration that proglucagon could be cleaved into multiple glucagon-like peptides, including several distinct isoforms of GLP-1. He then discovered that the truncated form of GLP-1(7-37) directly stimulated cyclic AMP formation, insulin secretion, and insulin gene expression; notably, it did so only when glucose levels were elevated.
leptonema Also leptotene stage. In meiosis, the first of five substages of prophase I, following interphase and preceding zygonema. During leptonema, the replicated chromosomes condense from diffuse chromatin into long, thin strands that are much more visible within the nucleus.
The Maillard reaction ( MY-ar(d); French: [majaʁ]) is a chemical reaction between amino acids and reducing sugars to create melanoidins, the compounds that give browned food its distinctive flavor. Seared steaks, fried dumplings, cookies and other kinds of biscuits, breads, toasted marshmallows, falafel and many other foods undergo this reaction. It is named after French chemist Louis Camille Maillard, who first described it in 1912 while attempting to reproduce biological protein synthesis. The reaction is a form of non-enzymatic browning which typically proceeds rapidly from around 140 to 165 °C (280 to 330 °F). Many recipes call for an oven temperature high enough to ensure that a Maillard reaction occurs. At higher temperatures, caramelization (the browning of sugars, a distinct process) and subsequently pyrolysis (final breakdown leading to burning and the development of acrid flavors) become more pronounced. The reactive carbonyl group of the sugar reacts with the nucleophilic amino group of the amino acid and forms a complex mixture of poorly characterized molecules responsible for a range of aromas and flavors. This process is accelerated in an alkaline environment (e.g., lye applied to darken pretzels; see lye roll), as the amino groups (RNH+3 → RNH2) are deprotonated, and hence have an increased nucleophilicity. This reaction is the basis for many of the flavoring industry's recipes. At high temperatures, a probable carcinogen called acrylamide can form. This can be discouraged by heating at a lower temperature, adding asparaginase, or injecting carbon dioxide.
Sources: en.wikipedia.org
A later vertebrate study identified protein tyrosine phosphatase receptor F (PTPRF), a member of the LAR family, as a conserved cognate receptor for the glucogenic actions of asprosin. In zebrafish, two Ptprf paralogs (ptprfa/b) are expressed in liver, bind asprosin with nanomolar affinity, and are required for asprosin-induced hyperglycemia and upregulation of gluconeogenic genes; soluble Ptprf ligand-binding domains neutralize the glucogenic effects and lower basal glucose, while ptprfa/b knockout fish show hypoglycemia and a blunted response to asprosin but normal responses to glucagon. In mice, PTPRF is expressed in liver and binds asprosin; Ptprf-deficient animals exhibit impaired asprosin-induced glucose production and reduced hepatic G6pc and Pck1 induction, and Ptprf deletion improves glucose tolerance without altering Olfr734 expression. Mechanistically, the same study showed that asprosin promotes insulin receptor and Akt dephosphorylation via PTPRF, counteracting insulin's suppression of gluconeogenesis and suggesting that chronic asprosin–PTPRF signaling contributes to hepatic insulin resistance. Several other independent studies have confirmed asprosin's glucogenic function.
The overwhelming majority of MRONJ diagnoses, however, were associated with intravenous administration of bisphosphonates (94%). Only the remaining 6% of cases arose in patients taking bisphosphonates orally. Although the total United States prescriptions for oral bisphosphonates exceeded 30 million in 2006, less than 10% of MRONJ cases were associated with patients taking oral bisphosphonate drugs. Studies have estimated that BRONJ occurs in roughly 20% of patients taking intravenous zoledronic acid for cancer therapy and in between 0–0.04% of patients taking orally administered bisphosphonates. Owing to prolonged embedding of bisphosphonate drugs in the bone tissues, the risk for MRONJ is elevated even after stopping the administration of the medication for several years. Patients who stopped taking anti-angiogenic drugs are exposed to the same risk as patients who have never taken the drugs because anti-angiogenic drugs do not normally reside in the body for a long period of time. Risk factors include:
A refrigerator car (or "reefer") is a refrigerated boxcar (US), a piece of railroad rolling stock designed to carry perishable freight at specific temperatures. Refrigerator cars differ from simple insulated boxcars and ventilated boxcars (commonly used for transporting fruit), neither of which are fitted with cooling apparatus. Reefers can be ice-cooled, come equipped with any one of a variety of mechanical refrigeration systems, or use carbon dioxide (as dry ice) or liquid nitrogen as a cooling agent. Milk cars (and other types of "express" reefers) may or may not include a cooling system, but are equipped with high-speed trucks and other modifications that allow them to travel with passenger trains.
In number theory and combinatorics, the rank of an integer partition is a certain integer associated with the partition. Dyson introduced the concept in a paper published in the journal Eureka. It was presented in the context of a study of certain congruence properties of the partition function discovered by the mathematician Srinivasa Ramanujan.
After testing the insulin on rabbits for more than a year, Eva was running out of conventional insulin and cautiously tried it on herself-–and it worked. In the Jewish ghetto where they were living, many other people with type 1 diabetes were also in dire need of insulin. Eva gave her insulin to two boys in a nearby hospital who were in diabetic comas. With a successful batch of homemade insulin, the Saxls began production of insulin for all people with Type 1 diabetes in the Shanghai Ghetto. In all, over 200 people survived between 1941 and 1945 and there were no fatalities reported as a result of tainted insulin. The Saxls left Shanghai after World War II and emigrated to the United States. Eva and Elliott P. Joslin, MD, founder of today's Joslin Diabetes Center in Boston, Massachusetts, befriended each other, and soon Dr. Joslin began inviting Eva to give lectures to groups of children and diabetes organizations. She became the first vocal spokesperson for Type 1 diabetes. Her husband worked for the United Nations.
Sources: en.wikipedia.org
=== Function === Vasopressin regulates the tonicity of body fluids. It is released from the posterior pituitary in response to hypertonicity and causes the kidneys to reabsorb solute-free water and return it to the circulation from the tubules of the nephron, thus returning the tonicity of the body fluids toward normal. An incidental consequence of this renal reabsorption of water is concentrated urine and reduced urine volume. AVP released in high concentrations may also raise blood pressure by inducing moderate vasoconstriction. AVP also may have a variety of neurological effects on the brain. It may influence pair-bonding in voles. The high-density distributions of vasopressin receptor AVPr1a in prairie vole ventral forebrain regions have been shown to facilitate and coordinate reward circuits during partner preference formation, critical for pair bond formation. A very similar substance, lysine vasopressin (LVP) or lypressin, has the same function in pigs and its synthetic version was used in human AVP deficiency, although it has been largely replaced by desmopressin.
==== Keratolytics ==== Keratolytics help the skin via exfoliation of built-up skin flakes and thereby remove scales. They are applied topically to the affected area. Keratolytics include urea, salicylic acid, coal tar, lactic acid, pyrithione zinc and propylene glycol. Coal tar shampoo formulations can be effective. Mo significant increased risk of cancer in human treatment with coal tar shampoos have been found. Caution is advised because coal tar is carcinogenic in animals, and heavy human occupational exposures increase cancer risks.
In more severe cases it is a consequence of dilation of the right ventricle, leading to displacement of the papillary muscles which control the valve's ability to close. Dilation of the right ventricle occurs secondary to ventricular septal defects, right to left shunting of blood, eisenmenger syndrome, hyperthyroidism, and pulmonary stenosis. Tricuspid insufficiency may also be the result of congenital defects of the tricuspid valve, such as Ebstein's anomaly.
=== Whistleblower retaliation lawsuit === In 2013, Bio-Rad's general counsel of 25 years, Sanford Wadler, followed internal whistleblowing procedures by reporting suspected bribery to Bio-Rad's audit committee, believing Bio-Rad had falsified books and records. The company fired him for making this report, which the courts found to amount to California common law wrongful discharge in violation of public policy. In 2017, a federal jury awarded Wadler with a $10.9 million settlement. This was appealed by Bio-Rad, and in 2019 the US appeals court reduced this to $7.96 million, plus $3.5 million in attorneys' fees and costs.
=== Cushing's syndrome === Cushing's syndrome develops as a result of long-term exposure to the hormone cortisol. Cushing's syndrome can either be exogenous or endogenous, depending on whether it is caused by an external or internal source, respectively. The intake of glucocorticoids, a type of corticosteroid, is a common cause for the development of exogenous Cushing's syndrome. Endogenous Cushing's syndrome can occur when the body produces excess cortisol. This occurs when the hypothalamus of the brain signals to the pituitary gland with excess corticotropin-releasing hormone, which in turn secretes adrenocorticotropin hormone (ACTH). ACTH then causes the adrenal glands to release cortisol into the blood. Signs of Cushing's syndrome include muscle weakness, easy bruising, weight gain, male-pattern hair growth (hirsutism), coloured stretch marks, and an excessively reddish complexion in the face. Cushing's syndrome can cause androgen excess and hence the signs and symptoms of hyperandrogenism.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.